Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer

ABSTRACT:

Simple Summary

Platinum-based chemotherapy and PARP inhibitors are two types of treatment that can benefit prostate cancer patients with mutations in genes that are involved in the repair of damage in the DNA. However, patients who receive one type of treatment may not respond as well to the other treatment later on. The optimal sequencing of these agents is still unclear. In this study, we looked at how 28 prostate cancer patients responded to both treatments. We found that patients generally responded best to the initially given treatment, but still over 40% of patients responded to the second treatment. We also found that the efficacy of the second given treatment was higher in the order of platinum-based chemotherapy first and PARP inhibitor second, compared to the opposite or

SUBMITTER: Slootbeek P 

PROVIDER: S-EPMC10216363 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature